Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.57 |
| ▸ | PKM | P14618 | 6/20 | 0.57 |
| ▸ | POLB | P06746 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 7/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21542230 | 0.91 | MAPT (0.58) | MAPTPKMPOLBSMN1; SMN2GAA | |
| SCHEMBL1957750 | 0.86 | MAPT (0.63) | MAPTPKMPOLBSMN1; SMN2GAA | |
| SCHEMBL21542231 | 0.83 | MAPT (0.57) | MAPTPKMPOLBSMN1; SMN2GAA | |
| SCHEMBL29482111 | 0.83 | MAPT (0.62) | MAPTPKMPOLBSMN1; SMN2GAA | |
| SCHEMBL21751695 | 0.83 | MAPT (0.59) | MAPTPKMPOLBSMN1; SMN2GAA | |
| SCHEMBL1958872 | 0.83 | MAPT (0.62) | MAPTPKMPOLBSMN1; SMN2GAA | |
| Hydrochloric Acid SCHEMBL21751590 | 0.82 | MAPT (0.58) | MAPTPKMPOLBSMN1; SMN2GAA | |
| SCHEMBL1957948 | 0.80 | MAPT (0.67) | MAPTPKMPOLBSMN1; SMN2GAA | |
| SCHEMBL21542182 | 0.79 | MAPT (0.47) | MAPTPKMPOLBSMN1; SMN2GAA | |
| SCHEMBL1700080 | 0.79 | MAPT (0.67) | MAPTPKMPOLBSMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3565815-B1 | COMPOUNDS AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS | FOCHON PHARMACEUTICALS LTD (CN) | 2024-03-13 | — | — | EP | disclosed |
| US-11053239-B2 | Compounds as BLC-2-selective apoptosis-inducing agents | FOCHON PHARMACEUTICALS, LTD. (CN) | 2021-07-06 | — | — | US | disclosed |
| US-20190345156-A1 | COMPOUNDS AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS | SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345156-A1 | COMPOUNDS AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS | BCL2, BAX, BCL2L1 | MAPT 3883/4885PKM 3856/4885POLB 1434/4885 |
| US-11053239-B2 | Compounds as BLC-2-selective apoptosis-inducing agents | BCL2, BAX, BAD | MAPT 3846/4885PKM 4544/4885POLB 1978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.